An experimental drug can delay disability progression in advanced multiple sclerosis patients Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis ...

Physical activity was associated with a lower risk of disability progression in multiple sclerosis (MS), longitudinal data showed. Compared with low physical activity, the risk of confirmed disability ...

Higher consumption of oily fish such as tuna and salmon or lean fish like cod and perch is associated with a reduced risk for disability progression in patients with multiple sclerosis (MS), a new ...

Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It can cause fatigue, trouble with balance and coordination, muscle weakness, and vision problems. Having MS doesn’t ...

Both oily and lean fish have properties that appear to help slow MS disability progression, according to a study. Higher amounts of fish intake correspond with lower measures of MS severity. Omega-3 ...

COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase 3 HERCULES ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

MINNEAPOLIS – In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications ...

Racial and ethnic differences in the severity, prognosis, and mortality of multiple sclerosis (MS) have been the focus of intensifying research over the last decade, and emerging evidence suggests ...

The largest study of its kind has found menopause is not associated with an increased risk of disability in women with multiple sclerosis (MS). Until now, the impact of reduced sex hormones on women ...

Tolebrutinib delayed disability progression by 31% in people with secondary progressive multiple sclerosis No drugs are currently approved to treat this type of MS WEDNESDAY, April 9, 2025 (HealthDay ...